Mechanistic analysis for anti-RANKL antibody drug associated severe adverse reactions
| Project/Area Number |
26670265
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | システム薬理学 / 毒性予測 / 分子標的薬 / 毒性予測法 / 医薬品副作用 |
|---|
| Outline of Final Research Achievements |
Denosumab, an anti-RANKL antibody drug, has been clinically used in recent years. However, it has been suspected that Denosumab has a potential to cause severe hypocalcemia. Since drug adverse reactions (ADR) often occur under the mechanisms which are not expected at development, there are difficulties in revealing such mechanisms in many cases. Overcoming these difficulties leads to mechanism based ADR management, resulting in safer drug therapy. Therefore, in this research, we have established a method to obtain the clues for ADR mechanisms based on systems-pharmacological techniques. With this method, we approached the mechanism behind Denosumab inducing hypocalcemia.
|
Report
(3 results)
Research Products
(5 results)
